MCID: VSC002
MIFTS: 54

Vascular Dementia malady

Categories: Mental diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Dementia

Aliases & Descriptions for Vascular Dementia:

Name: Vascular Dementia 12 14
Dementia, Vascular 42 69
Dementia, Vascular, Susceptibility to 13
Dementia, Multi-Infarct 42
Multi Infarct Dementia 12
Multi-Infarct Dementia 69
Multifocal Dementia 12
Dementia Vascular 52

Classifications:



Summaries for Vascular Dementia

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

MalaCards based summary : Vascular Dementia, also known as dementia, vascular, is related to dementia and binswanger's disease. An important gene associated with Vascular Dementia is APOE (Apolipoprotein E), and among its related pathways/superpathways are Neuroscience and Copper homeostasis. The drugs Dopamine and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 71 Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI),... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
id Related Disease Score Top Affiliating Genes
1 dementia 11.5
2 binswanger's disease 11.3
3 subcortical arteriosclerotic encephalopathy 10.9
4 dementia - subcortical 10.7
5 cadasil 10.6
6 vascular disease 10.6
7 keratosis palmoplantaris striata 10.3 APOE MAPT
8 lupus erythematosus panniculitis 10.3 ACE APOE
9 cerebritis 10.3
10 mcleod neuroacanthocytosis syndrome 10.3 MAPT PSEN1
11 gata1-related thrombocytopenia 10.3 MAPT PSEN1
12 hereditary paraganglioma-pheochromocytoma syndromes 10.3 MAPT PSEN1
13 alzheimer disease 10.3
14 pars planitis 10.3 ACE APOE MTHFR
15 severe congenital nemaline myopathy 10.2 APOE MAPT PSEN1
16 asphyxia neonatorum 10.2 ACE APOE PON1
17 adult mesenchymal chondrosarcoma 10.2 ACHE MAPT PSEN1
18 intra-abdominal lymph node mast cell malignancy 10.2 ACE APOE MTHFR
19 encephalitozoonosis 10.2 APOE APP PSEN1
20 gait apraxia 10.2 ACE APOE PON1
21 ectodermal dysplasia mental retardation syndactyly 10.2 APP PSEN1
22 juvenile amyotrophic lateral sclerosis with dementia 10.2 ACE APP MAPT
23 intracranial cysts 10.2 MTHFR VEGFA
24 kartagener syndrome 10.2 ACE MTHFR
25 intracranial structure hemangioma 10.2 APP MAPT PSEN1
26 schistosomiasis 10.2 APOE MTHFR NOTCH3
27 homocystinuria caused by cystathionine beta-synthase deficiency 10.2 APOE PRNP
28 iron metabolism disease 10.2 ACE APOE
29 siberian tick typhus 10.2 ACHE CHAT PSEN1
30 pulmonary systemic sclerosis 10.2 APOE MAPT SERPINA3
31 dementia pugilistica 10.2
32 interstitial emphysema 10.2 ACE MTHFR NOTCH3
33 vernal conjunctivitis 10.1 ACE MTHFR VEGFA
34 urethritis 10.1 APOE MBP PSEN1
35 angina pectoris 10.1 APOE MAPT PSEN1
36 foxp2-related speech and language disorders 10.1 APP PSEN1
37 isolated anterior cervical hypertrichosis 10.1 SERPINA3 VEGFA
38 citrullinemia, type ii, neonatal-onset 10.1 ACE PON1 VEGFA
39 syringocystadenoma papilliferum 10.1 APOE APP PRNP
40 macular degeneration, age-related, 12 10.1 ACE APOE MTHFR PON1
41 cerebrovascular disease 10.1
42 vaginal spindle cell epithelioma 10.1 APP MAPT PRNP
43 budd-chiari syndrome 10.1 ACE APOE MTHFR NOTCH3
44 allergic bronchopulmonary aspergillosis, familial 10.0 APOE APP MAPT SERPINA3
45 autoimmune disease of urogenital tract 10.0 APOE MAPT PRNP PSEN1
46 cardiomyopathy, dilated, 1u 10.0 ACHE APOE APP MAPT PSEN1
47 autoimmune-related retinopathy and optic neuropathy 10.0 ACE APOE PON1 VEGFA
48 limited scleroderma 10.0 APOE APP PSEN1 SERPINA3
49 scrotum basal cell carcinoma 10.0 MAPT PRNP
50 ichthyosis lamellar 2 10.0 APOE APP MAPT MBP

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 BCHE CHAT CST3 MAPT MBP MTHFR
2 growth/size/body region MP:0005378 10.29 ACE ACHE APOE APP CHAT MAPT
3 behavior/neurological MP:0005386 10.28 ACE ACHE APOE APP CHAT MAPT
4 mortality/aging MP:0010768 10.25 ACE ACHE APOE APP BCHE CHAT
5 hematopoietic system MP:0005397 10.19 PRNP PSEN1 VEGFA ACE ACHE APOE
6 cardiovascular system MP:0005385 10.18 ACE APOE CHAT CST3 MAPT NOTCH3
7 nervous system MP:0003631 10.1 VEGFA ACHE APOE APP CHAT CST3
8 muscle MP:0005369 10.07 ACHE APOE APP CHAT CST3 MAPT
9 integument MP:0010771 10.06 PRNP PSEN1 VEGFA APOE APP MAPT
10 limbs/digits/tail MP:0005371 9.91 APOE CHAT MTHFR PRNP PSEN1 VEGFA
11 no phenotypic analysis MP:0003012 9.8 ACHE APOE APP MAPT MTHFR PRNP
12 reproductive system MP:0005389 9.77 ACE ACHE APOE APP BCHE CHAT
13 normal MP:0002873 9.76 VEGFA APP CHAT MAPT MBP NOTCH3
14 vision/eye MP:0005391 9.32 PSEN1 VEGFA ACHE APOE CHAT MAPT

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
4
Memantine Approved, Investigational Phase 4 19982-08-2 4054
5
Cilostazol Approved Phase 4,Phase 2 73963-72-1 2754
6
Nimodipine Approved Phase 4 66085-59-4 4497
7
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
8
Menthol Approved Phase 4,Phase 2,Phase 3 2216-51-5 16666
9
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
10
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
11
Ramipril Approved Phase 4 87333-19-5 5362129
12
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
13
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651 908828, 9651
14 Piracetam Approved Phase 4 7491-74-9
15
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
16
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
17
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
18
Nicergoline Approved Phase 4 27848-84-6 34040
19
Pravastatin Approved Phase 4 81093-37-0 54687
20
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
21
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
22
Fluvastatin Approved Phase 4 93957-54-1 1548972
23
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
24
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
25
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
26
Allopurinol Approved Phase 4 315-30-0 2094
27
Choline Approved, Nutraceutical Phase 4 62-49-7 305
28
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
29 Analgesics Phase 4,Phase 2
30 calcium channel blockers Phase 4,Phase 2,Phase 3
31
protease inhibitors Phase 4,Phase 3,Phase 2
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33
Serotonin Phase 4,Phase 3 50-67-9 5202
34 Muscarinic Antagonists Phase 4
35 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Cholinergic Antagonists Phase 4
37 Serotonin Agents Phase 4,Phase 3
38 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Serotonin Uptake Inhibitors Phase 4,Phase 3
40 Neuroprotective Agents Phase 4,Phase 3,Phase 2
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Cyclooxygenase Inhibitors Phase 4
43 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
44 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
45 Analgesics, Non-Narcotic Phase 4,Phase 2
46 Parasympatholytics Phase 4
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
48 Dopamine Agents Phase 4,Phase 3,Phase 2
49 Vasodilator Agents Phase 4,Phase 2,Phase 3
50 Anti-Asthmatic Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 244)
id Name Status NCT ID Phase
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4
3 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
4 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4
5 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4
6 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
7 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4
8 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4
9 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4
10 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4
11 Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Completed NCT01009476 Phase 4
12 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4
13 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4
14 The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia Completed NCT01363648 Phase 4
15 RIVastigmine In Vascular cognitivE Impairment Completed NCT00669344 Phase 4
16 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4
17 Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke Completed NCT01109836 Phase 4
18 Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities Completed NCT01645943 Phase 4
19 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed NCT00980785 Phase 4
20 Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue Recruiting NCT02996916 Phase 4
21 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
22 Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals Recruiting NCT02472028 Phase 4
23 A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease Recruiting NCT02660983 Phase 4
24 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4
25 Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives Recruiting NCT01563731 Phase 4
26 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Active, not recruiting NCT01932203 Phase 4
27 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4
28 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
29 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3
30 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3
31 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3
32 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3
33 Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease Completed NCT00165737 Phase 3
34 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3
35 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3
36 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3
37 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3
38 Serotonergic Pharmacotherapy for Agitation of Dementia Completed NCT00009204 Phase 3
39 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3
40 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3
41 Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes Completed NCT00145925 Phase 3
42 Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT00188812 Phase 3
43 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3
44 Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) Completed NCT01582854 Phase 3
45 Women's Isoflavone Soy Health (WISH) Trial Completed NCT00118846 Phase 2, Phase 3
46 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Recruiting NCT02453932 Phase 3
47 Symptomatic Treatment of Vascular Cognitive Impairment Recruiting NCT02098824 Phase 2, Phase 3
48 MIND Diet Intervention and Cognitive Decline Recruiting NCT02817074 Phase 3
49 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3
50 The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND Recruiting NCT02993367 Phase 2, Phase 3

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

39
Brain, Cortex, Testes, Endothelial, Temporal Lobe, Heart, Hypothalamus

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 739)
id Title Authors Year
1
Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( 27901381 )
2017
2
Prevention of hypertension-induced vascular dementia by Lactobacillus paracasei subsp. paracasei NTU 101-fermented products. ( 27937042 )
2017
3
White matter damage and glymphatic dysfunction in a model of vascular dementia in rats with no prior vascular pathologies. ( 27940353 )
2017
4
Environmental Enrichment Improves Spatial Learning and Memory in Vascular Dementia Rats with Activation of Wnt/I^-Catenin Signal Pathway. ( 28082734 )
2017
5
Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. ( 27864280 )
2017
6
Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia. ( 27845241 )
2017
7
Neuroprotective Effects of Nicorandil in Chronic Cerebral Hypoperfusion-Induced Vascular Dementia. ( 27622862 )
2016
8
Endogenous Polysialic Acid Based Micelles for Calmodulin Antagonist Delivery against Vascular Dementia. ( 27750011 )
2016
9
Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. ( 27966748 )
2016
10
Mechanisms of acupuncture on vascular dementia-A review of animal studies. ( 28034725 )
2016
11
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. ( 27430267 )
2016
12
Effects of In-vitro Cultured Calculus Bovis on Learning and Memory Impairments of Hyperlipemia Vascular Dementia Rats. ( 27616028 )
2016
13
Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. ( 27806707 )
2016
14
Gastrin-releasing peptide facilitates glutamatergic transmission in the hippocampus and effectively prevents vascular dementia induced cognitive and synaptic plasticity deficits. ( 27539743 )
2016
15
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study. ( 27747317 )
2016
16
Hydroxysafflor yellow A increases BDNF and NMDARs in the hippocampus in A vascular dementia rat model. ( 27086971 )
2016
17
Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. ( 27062261 )
2016
18
Neuroprotective and memory enhancing effects of auraptene in a rat model of vascular dementia: Experimental study and histopathological evaluation. ( 27130820 )
2016
19
Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. ( 27662637 )
2016
20
Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia. ( 27487766 )
2016
21
Antagonism of endothelin (ETA and ETB) receptors during renovascular hypertension-induced vascular dementia improves cognition. ( 27189349 )
2016
22
Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. ( 27127486 )
2016
23
A rat model of vascular dementia for evaluating Chinese medicine prescriptions. ( 26956462 )
2016
24
Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke. ( 27165956 )
2016
25
OS 25-05 Mas1 RECEPTOR DEFICIENCY DOES NOT DETERIORATE COGNITIVE FUNCTION IN VASCULAR DEMENTIA MODEL OF MICE. ( 27754130 )
2016
26
What is new in vascular dementia? ( 27806713 )
2016
27
Lower Death Risk for Vascular Dementia than for Alzheimer's Disease with Postmenopausal Hormone Therapy Users. ( 27906568 )
2016
28
Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia. ( 26980008 )
2016
29
Selective modulator of cannabinoid receptor type 2 reduces memory impairment and infarct size during cerebral hypoperfusion and vascular dementia. ( 27586843 )
2016
30
Gradual Carotid Artery Stenosis in Mice Closely Replicates Hypoperfusive Vascular Dementia in Humans. ( 27068624 )
2016
31
GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia. ( 27181927 )
2016
32
Update on Vascular Dementia. ( 27502303 )
2016
33
Bee Venom Ameliorates Cognitive Dysfunction Caused by Neuroinflammation in an Animal Model of Vascular Dementia. ( 27686075 )
2016
34
Neuropsychiatric characteristics of PiB-negative subcortical vascular dementia versus behavioral variant frontotemporal dementia. ( 27454622 )
2016
35
Protective Effect of Low-Intensity Pulsed Ultrasound on Memory Impairment and Brain Damage in a Rat Model of Vascular Dementia. ( 27399328 )
2016
36
Alzheimer and vascular dementia in the elderly patients. ( 27882038 )
2016
37
Selective modulator of cannabinoid receptor type 2 (CB2) against biochemical alterations and brain damage in chronic cerebral hypoperfusion induced vascular dementia. ( 27599483 )
2016
38
Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population. ( 27163798 )
2016
39
At-home tDCS of the left dorsolateral prefrontal cortex improves visual short-term memory in mild vascular dementia. ( 27653887 )
2016
40
Inhibited Expression of I+4I^2 Nicotinic Acetylcholine Receptor in Blood Leukocytes of Chinese Patients with Vascular Dementia and in Blood Leukocytes as Well as the Hippocampus of Brain from Ischemic Rats. ( 26858154 )
2016
41
Regional MRI Diffusion, White-Matter Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular Dementia. ( 27074295 )
2016
42
Depression and the risk of vascular dementia: a population-based retrospective cohort study. ( 27161941 )
2016
43
miRNAs Plasma Profiles in Vascular Dementia: Biomolecular Data and Biomedical Implications. ( 26973465 )
2016
44
Molecular Mechanisms of Vascular Dementia: What Can Be Learned from Animal Models of Chronic Cerebral Hypoperfusion? ( 27206432 )
2016
45
Cognitive variations among vascular dementia subtypes caused by small-, large-, or mixed-vessel disease. ( 27478455 )
2016
46
Cognitive profiles in degenerative dementia without evidence of small vessel pathology and small vessel vascular dementia. ( 27655157 )
2016
47
Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease. ( 27079711 )
2016
48
Neuroprotective effects of tetrandrine against vascular dementia. ( 27127485 )
2016
49
Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer's Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus: AA New/Old Potential Target. ( 27497479 )
2016
50
Association between Helicobacter pylori infection and carotid atherosclerosis in patients with vascular dementia. ( 26944122 )
2016

Variations for Vascular Dementia

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.85 ACHE APP PRNP PSEN1 VEGFA
2 endoplasmic reticulum lumen GO:0005788 9.8 APOE APP BCHE CST3
3 axon GO:0030424 9.78 APP CST3 MAPT PSEN1
4 growth cone GO:0030426 9.69 APP MAPT PSEN1
5 extracellular region GO:0005576 9.65 ACE ACHE APOE APP BCHE CST3
6 blood microparticle GO:0072562 9.62 APOE BCHE PON1 SERPINA3
7 neuronal cell body GO:0043025 9.55 APOE CST3 MAPT MBP PSEN1
8 platelet alpha granule lumen GO:0031093 9.54 APP SERPINA3 VEGFA
9 nuclear envelope lumen GO:0005641 9.43 APP BCHE
10 neuromuscular junction GO:0031594 9.43 ACHE APP PSEN1
11 ciliary rootlet GO:0035253 9.4 APP PSEN1
12 extracellular space GO:0005615 9.28 ACE ACHE APOE APP BCHE CST3

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.81 APOE APP CST3 PSEN1
2 platelet degranulation GO:0002576 9.8 APP SERPINA3 VEGFA
3 negative regulation of peptidase activity GO:0010466 9.8 APP CST3 SERPINA3
4 Notch signaling pathway GO:0007219 9.79 APP NOTCH3 PSEN1
5 response to toxic substance GO:0009636 9.77 CST3 MBP PON1
6 cholesterol metabolic process GO:0008203 9.72 APOE APP PON1
7 forebrain development GO:0030900 9.7 APP NOTCH3 PSEN1
8 regulation of microtubule cytoskeleton organization GO:0070507 9.62 MAPT PHLDB2
9 Notch receptor processing GO:0007220 9.61 NOTCH3 PSEN1
10 learning or memory GO:0007611 9.61 APP PRNP PSEN1
11 positive regulation of cholesterol efflux GO:0010875 9.59 APOE PON1
12 cellular copper ion homeostasis GO:0006878 9.58 APP PRNP
13 beta-amyloid metabolic process GO:0050435 9.58 ACE PSEN1
14 neurotransmitter biosynthetic process GO:0042136 9.57 ACHE CHAT
15 supramolecular fiber organization GO:0097435 9.56 CST3 MAPT
16 response to folic acid GO:0051593 9.54 BCHE MTHFR
17 amyloid fibril formation GO:1990000 9.49 APP MAPT
18 cellular response to beta-amyloid GO:1904646 9.48 APP PSEN1
19 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.46 ACE VEGFA
20 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.4 APP PSEN1
21 negative regulation of long-term synaptic potentiation GO:1900272 9.37 APOE PRNP
22 artery morphogenesis GO:0048844 9.33 APOE NOTCH3 VEGFA
23 astrocyte activation involved in immune response GO:0002265 9.32 APP PSEN1
24 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.26 APP PSEN1
25 amyloid precursor protein metabolic process GO:0042982 9.13 ACHE APOE PSEN1
26 response to oxidative stress GO:0006979 9.02 APOE APP CST3 PRNP PSEN1

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 APP BCHE MAPT NOTCH3
2 peptidase inhibitor activity GO:0030414 9.54 APP CST3 SERPINA3
3 identical protein binding GO:0042802 9.5 APOE APP BCHE CST3 MAPT PRNP
4 receptor agonist activity GO:0048018 9.4 MAPT VEGFA
5 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
6 cholinesterase activity GO:0004104 9.26 ACHE BCHE
7 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE
8 beta-amyloid binding GO:0001540 9.02 ACHE APOE BCHE CST3 PRNP

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....